FAQ on TransCode Therapeutics' Phase 1a Trial of TTX-MC138 RNA Cancer Therapy
Summary
What is TTX-MC138?
TTX-MC138 is an RNA-based therapeutic developed by TransCode Therapeutics, targeting microRNA-10b in metastatic cancer, designed to treat tumors overexpressing this biomarker.
What progress has been made in the Phase 1a trial of TTX-MC138?
Thirteen patients have received at least one dose across four dosing levels with no significant toxicities observed, and early data indicate target engagement and a dose-response relationship, supporting advancement to Phase 1b.
How many patients remain in the trial and what are the results so far?
Eight patients remain in the trial, with two showing stable disease after seven months, indicating promising early signs of the therapy’s potential effectiveness.
What is the significance of the Phase 1a trial results?
The results, showing no significant toxicities and early signs of target engagement and dose-response, support the advancement of TTX-MC138 to Phase 1b for further evaluation of safety and anti-tumor activity.
Where can I find more information about the Phase 1a trial?
More information can be found in the full press release at https://ibn.fm/OjVf3 and on TransCode Therapeutics’ website at https://ir.transcodetherapeutics.com/.
What is TransCode Therapeutics’ focus?
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.
What makes TTX-MC138 unique?
TTX-MC138 targets microRNA-10b, a well-documented biomarker of metastasis, making it a unique approach to treating metastatic tumors that overexpress this biomarker.
What are the next steps for TTX-MC138?
Following the promising Phase 1a results, the next step is advancing TTX-MC138 to Phase 1b for expanded safety and anti-tumor activity evaluation.
How can I learn more about TransCode Therapeutics?
For more information about TransCode Therapeutics, visit their investor relations website at https://ir.transcodetherapeutics.com/.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 118091